RGD-K5
FDG
Pre-treatment
Post 2-dose bevacizumab
Post 4-dose bevacizumab
Pre-treatment
Post 4-dose bevacizumab
Primary tumor
1.8
3.1 (72%)
1.9 (5%)
8.7
2.4 (-72%)
Table 3:
The SUVmax of the primary tumor of Subject-2, and the FDG percentage reduction after treatment compared to the baseline value.